Reuters logo
BRIEF-Biomarin announces Kuvan patent challenge settlement
April 13, 2017 / 12:56 PM / 7 months ago

BRIEF-Biomarin announces Kuvan patent challenge settlement

April 13 (Reuters) - Biomarin Pharmaceutical Inc

* Biomarin announces Kuvan (sapropterin dihydrochloride) patent challenge settlement

* Biomarin Pharmaceutical Inc - retains exclusive U.S. rights until October 1, 2020

* Biomarin Pharmaceutical Inc - under settlement, Biomarin will grant par a non-exclusive license to its patents related to Kuvan Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below